aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Biotechnology Value Fund (BVF) is a San Francisco-based private investment partnership that focuses on fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has concentrated on building long-term investments in small-cap biotechnology companies. The firm typically engages in Series A to Series E rounds, as well as post-IPO equity and debt investments, with a commitment to rigorous diligence and ongoing monitoring of its portfolio.
BVF's notable portfolio companies include 4D Molecular Therapeutics, Aadi Bioscience, Alpine Immune Sciences, and Black Diamond Therapeutics. The firm is known for its collaborative approach, working closely with portfolio companies to support their growth and success. Key partners and decision-makers at BVF bring extensive experience and industry knowledge, contributing to the firm's reputation for strategic and impactful investments in the biotechnology sector.
Also Known As
Biotechnology Value Fund
Operating Status
Active
Biotechnology Value Fund Address
San Francisco,
California
94104
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts